Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Rees

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Current Opinion in Lipidology|July 9, 2008
Therapy and clinical trials: metabolic syndrome and cardiovascular risk managementMahamood Edavalath, Alan Rees
Current Opinion in Lipidology|March 12, 2009
Diabetes and cardiovascular disease: new perspectivesRajesh Peter, Alan Rees
Current Opinion in Lipidology|September 6, 2013
A potential role for monoclonal antibodies in clinical lipidology: can we look beyond statins?Atul Kalhan, Alan Rees
Current Opinion in Lipidology|January 9, 2014
Use of monoclonal antibodies for proprotein convertase subtilisin kexin type 9 inhibition: issues with efficacy, tolerability and safetyGautam Das, Alan Rees
Current Opinion in Lipidology|September 12, 2012
Inhibition of PCSK9: is this the way forward for managing residual risk?Sharmistha Roy Chowdhury, Alan Rees
Current Opinion in Lipidology|March 10, 2016
Do the mechanisms by which LDL-c levels are reduced influence the extent of clinical benefit which subsequently accrues?Catrin A Higgins, Alan Rees
Current Opinion in Lipidology|May 14, 2010
Therapy and clinical trials: nicotinic acid in the management of atherosclerotic diseaseManeesh Vasant Udiawar, Alan Rees
Current Opinion in Lipidology|March 9, 2017
The onward march of PCSK9 inhibitionCatrin A Higgins, Alan Rees
Current Opinion in Lipidology|January 27, 2010
Apolipoprotein B: can we continue to ignore?Srinivasa P Munigoti, Alan Rees
Current Opinion in Lipidology|January 15, 2011
Evidence for use of fibrates in diabetic dyslipidemia: are we looking hard enough?Srinivasa P Munigoti, Alan Rees
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Current Opinion in Lipidology|July 9, 2008
Therapy and clinical trials: metabolic syndrome and cardiovascular risk managementMahamood Edavalath, Alan Rees
Current Opinion in Lipidology|March 12, 2009
Diabetes and cardiovascular disease: new perspectivesRajesh Peter, Alan Rees
Current Opinion in Lipidology|September 6, 2013
A potential role for monoclonal antibodies in clinical lipidology: can we look beyond statins?Atul Kalhan, Alan Rees
Current Opinion in Lipidology|January 9, 2014
Use of monoclonal antibodies for proprotein convertase subtilisin kexin type 9 inhibition: issues with efficacy, tolerability and safetyGautam Das, Alan Rees
Current Opinion in Lipidology|September 12, 2012
Inhibition of PCSK9: is this the way forward for managing residual risk?Sharmistha Roy Chowdhury, Alan Rees
Current Opinion in Lipidology|March 10, 2016
Do the mechanisms by which LDL-c levels are reduced influence the extent of clinical benefit which subsequently accrues?Catrin A Higgins, Alan Rees
Current Opinion in Lipidology|May 14, 2010
Therapy and clinical trials: nicotinic acid in the management of atherosclerotic diseaseManeesh Vasant Udiawar, Alan Rees
Current Opinion in Lipidology|March 9, 2017
The onward march of PCSK9 inhibitionCatrin A Higgins, Alan Rees
Current Opinion in Lipidology|January 27, 2010
Apolipoprotein B: can we continue to ignore?Srinivasa P Munigoti, Alan Rees
Current Opinion in Lipidology|January 15, 2011
Evidence for use of fibrates in diabetic dyslipidemia: are we looking hard enough?Srinivasa P Munigoti, Alan Rees
Pageof 5